Publication | Closed Access

Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes

Soft-tissue InfectionsAntimicrobial SusceptibilityHealth SciencesAntibioticsMicrobiological OutcomesDrug-resistant Pseudomonas AeruginosaProsthetic Joint InfectionsAntimicrobial TherapyAntimicrobial ChemotherapyAntimicrobial CompoundMedicineClinical MicrobiologyAntimicrobial ResistanceDrug Resistance